INOZYME PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price

INOZYME PHARMA, INC. had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $7.59 per share as of 2024-12-31, per its 10-K filed 2025-03-10.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2025-03-10

2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $7.59.
2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $8.05.
2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $9.26.
2022-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $9.29.

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
2024-12-31	$7.59 10-K · filed 2025-03-10
2023-12-31	$8.05 10-K · filed 2024-03-12
2022-12-31	$9.26 10-K · filed 2023-03-22
2022-09-30	$9.29 10-Q · filed 2022-11-10
2022-06-30	$8.84 10-Q · filed 2022-08-15
2022-03-31	$8.29 10-Q · filed 2022-05-10
2021-12-31	$7.09 10-K · filed 2022-03-15
2021-09-30	$6.17 10-Q · filed 2021-11-09
2021-06-30	$5.38 10-Q · filed 2021-08-11
2021-03-31	$3.31 10-Q · filed 2021-05-12
2020-12-31	$2.61 10-K · filed 2021-03-25
2020-09-30	$1.96 10-Q · filed 2020-11-12
2020-06-30	$1.29 10-Q · filed 2020-09-03
2019-12-31	$1.15 10-Q · filed 2020-09-03